Aliases & Classifications for Adenoma

MalaCards integrated aliases for Adenoma:

Name: Adenoma 12 72 51 14 69
Acinar Cell Adenoma 12 69
Acinic Cell Adenoma 12
Adenomas 12

Classifications:



External Ids:

Disease Ontology 12 DOID:657
MeSH 41 D000236
NCIt 46 C2855 C4196

Summaries for Adenoma

Disease Ontology : 12 A cell type benign neoplasm that is composed_of epithelial tissue in which tumor cells form glands or glandlike structures.

MalaCards based summary : Adenoma, also known as acinar cell adenoma, is related to pituitary adenoma 1, multiple types and pleomorphic adenoma. An important gene associated with Adenoma is PLAG1 (PLAG1 Zinc Finger), and among its related pathways/superpathways are PI3K-Akt signaling pathway and Endometrial cancer. The drugs Erythromycin and Aspirin have been mentioned in the context of this disorder. Affiliated tissues include pituitary, colon and thyroid, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Wikipedia : 72 An adenoma (from Greek αδένας, adeno-, \"gland\" + -ώμα, -oma, \"tumor\") (/ˌædɪˈnoʊmə/; plural adenomas... more...

Related Diseases for Adenoma

Diseases related to Adenoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 855)
# Related Disease Score Top Affiliating Genes
1 pituitary adenoma 1, multiple types 34.2 AIP PRL SST
2 pleomorphic adenoma 34.2 PLAG1 PLAGL1 PLAGL2
3 acth-secreting pituitary adenoma 34.2 GNAS POMC PRL
4 villous adenoma 34.2 GNAS KRAS SST
5 parathyroid adenoma 34.1 CCND1 CTNNB1 RET
6 colorectal adenoma 34.0 CTNNB1 KRAS MLH1 MSH2
7 pituitary adenoma 34.0 AIP GNAS POMC PRL SST
8 pituitary adenoma, prolactin-secreting 34.0 AIP GNAS POMC PRL SST
9 sebaceous adenoma 34.0 MLH1 MSH2
10 bronchus adenoma 33.8 POMC SST
11 growth hormone secreting pituitary adenoma 33.7 AIP GNAS PRL SST
12 acidophil adenoma 33.7 POMC SST
13 periampullary adenoma 33.7 KRAS SST
14 functioning pituitary adenoma 33.5 AIP POMC PRL SST
15 bronchial adenomas/carcinoids childhood 33.3 POMC SST
16 acromegaly 32.9 AIP GNAS POMC PRL SST
17 endometrial adenocarcinoma 32.5 CTNNB1 KRAS MLH1
18 tsh producing pituitary tumor 32.4 PRL SST
19 multiple endocrine neoplasia, type i 32.4 GNAS PRL RET SST
20 mismatch repair cancer syndrome 32.4 CTNNB1 MLH1 MSH2
21 chiasmal syndrome 32.4 POMC PRL SST
22 primary pigmented nodular adrenocortical disease 32.4 CTNNB1 GNAS POMC
23 adrenal gland hyperfunction 32.3 POMC PRL SST
24 hyperpituitarism 32.0 AIP POMC PRL SST
25 mutyh-associated polyposis 31.9 KRAS SMAD4
26 colorectal cancer 31.3 AXIN2 CCND1 CTNNB1 GNAS KRAS MLH1
27 primary hyperparathyroidism 31.0 CCND1 PRL RET
28 pituitary apoplexy 31.0 AIP POMC PRL
29 mccune-albright syndrome 30.6 GNAS PRL SST
30 hyperthyroidism 30.6 GNAS PRL SST
31 pituitary tumors 30.6 AIP GNAS POMC PRL SST
32 carney complex variant 30.6 AIP GNAS POMC
33 pituitary carcinoma 30.5 GNAS POMC SST
34 familial adenomatous polyposis 30.5 AXIN2 CCND1 CTNNB1 KRAS MLH1 MSH2
35 hyperprolactinemia 30.5 POMC PRL SST
36 colitis 30.5 CTNNB1 MLH1 MSH2 SMAD4
37 colorectal adenocarcinoma 30.4 CTNNB1 KRAS MLH1 MSH2
38 lynch syndrome 30.4 CCND1 CTNNB1 KRAS MLH1 MSH2
39 adenocarcinoma 30.3 CCND1 CTNNB1 KRAS MLH1 MSH2 RET
40 adenohypophysitis 30.3 POMC PRL
41 thyroid cancer 30.2 CCND1 CTNNB1 GNAS KRAS RET
42 amenorrhea 30.2 LHCGR POMC PRL
43 intrahepatic cholangiocarcinoma 30.2 CCND1 CTNNB1 KRAS
44 colon adenocarcinoma 30.2 CTNNB1 KRAS MLH1
45 neurofibromatosis, type iv, of riccardi 29.9 KRAS MLH1 MSH2 RET SST
46 fibrous dysplasia 29.8 GNAS PRL SST
47 pancreas adenocarcinoma 29.8 CTNNB1 KRAS SMAD4
48 gastric cancer 29.6 CCND1 CTNNB1 KRAS MLH1 MSH2 SMAD4
49 gallbladder cancer 29.5 CCND1 KRAS MLH1
50 colonic benign neoplasm 29.5 AXIN2 CTNNB1 KRAS MLH1 MSH2

Graphical network of the top 20 diseases related to Adenoma:



Diseases related to Adenoma

Symptoms & Phenotypes for Adenoma

GenomeRNAi Phenotypes related to Adenoma according to GeneCards Suite gene sharing:

25 (show all 47)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-107 10.6 SMAD4
2 Increased shRNA abundance (Z-score > 2) GR00366-A-11 10.6 TGFBR2 SMAD4 CTNNB1
3 Increased shRNA abundance (Z-score > 2) GR00366-A-110 10.6 PLAGL2
4 Increased shRNA abundance (Z-score > 2) GR00366-A-113 10.6 CTNNB1
5 Increased shRNA abundance (Z-score > 2) GR00366-A-12 10.6 TGFBR2
6 Increased shRNA abundance (Z-score > 2) GR00366-A-121 10.6 TGFBR2
7 Increased shRNA abundance (Z-score > 2) GR00366-A-123 10.6 TGFBR2
8 Increased shRNA abundance (Z-score > 2) GR00366-A-126 10.6 CCND1
9 Increased shRNA abundance (Z-score > 2) GR00366-A-127 10.6 PLAGL2
10 Increased shRNA abundance (Z-score > 2) GR00366-A-130 10.6 RET
11 Increased shRNA abundance (Z-score > 2) GR00366-A-132 10.6 RET TGFBR2
12 Increased shRNA abundance (Z-score > 2) GR00366-A-146 10.6 PLAGL2
13 Increased shRNA abundance (Z-score > 2) GR00366-A-147 10.6 TGFBR2
14 Increased shRNA abundance (Z-score > 2) GR00366-A-152 10.6 TGFBR2 CCND1
15 Increased shRNA abundance (Z-score > 2) GR00366-A-16 10.6 CCND1
16 Increased shRNA abundance (Z-score > 2) GR00366-A-162 10.6 TGFBR2
17 Increased shRNA abundance (Z-score > 2) GR00366-A-163 10.6 CCND1
18 Increased shRNA abundance (Z-score > 2) GR00366-A-164 10.6 TGFBR2 RET
19 Increased shRNA abundance (Z-score > 2) GR00366-A-176 10.6 RET
20 Increased shRNA abundance (Z-score > 2) GR00366-A-177 10.6 CCND1 CTNNB1
21 Increased shRNA abundance (Z-score > 2) GR00366-A-186 10.6 TGFBR2
22 Increased shRNA abundance (Z-score > 2) GR00366-A-188 10.6 TGFBR2
23 Increased shRNA abundance (Z-score > 2) GR00366-A-197 10.6 CTNNB1
24 Increased shRNA abundance (Z-score > 2) GR00366-A-199 10.6 CCND1
25 Increased shRNA abundance (Z-score > 2) GR00366-A-21 10.6 SMAD4 CCND1
26 Increased shRNA abundance (Z-score > 2) GR00366-A-210 10.6 CCND1
27 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.6 TGFBR2
28 Increased shRNA abundance (Z-score > 2) GR00366-A-25 10.6 SMAD4 RET CCND1 PLAGL2
29 Increased shRNA abundance (Z-score > 2) GR00366-A-36 10.6 CCND1
30 Increased shRNA abundance (Z-score > 2) GR00366-A-39 10.6 TGFBR2
31 Increased shRNA abundance (Z-score > 2) GR00366-A-42 10.6 SMAD4
32 Increased shRNA abundance (Z-score > 2) GR00366-A-43 10.6 SMAD4
33 Increased shRNA abundance (Z-score > 2) GR00366-A-46 10.6 SMAD4
34 Increased shRNA abundance (Z-score > 2) GR00366-A-47 10.6 CTNNB1
35 Increased shRNA abundance (Z-score > 2) GR00366-A-49 10.6 CTNNB1
36 Increased shRNA abundance (Z-score > 2) GR00366-A-52 10.6 RET
37 Increased shRNA abundance (Z-score > 2) GR00366-A-54 10.6 SMAD4
38 Increased shRNA abundance (Z-score > 2) GR00366-A-63 10.6 PLAGL2
39 Increased shRNA abundance (Z-score > 2) GR00366-A-67 10.6 CTNNB1
40 Increased shRNA abundance (Z-score > 2) GR00366-A-7 10.6 TGFBR2
41 Increased shRNA abundance (Z-score > 2) GR00366-A-73 10.6 TGFBR2 SMAD4 RET PLAGL2 CTNNB1
42 Increased shRNA abundance (Z-score > 2) GR00366-A-74 10.6 SMAD4 CTNNB1
43 Increased shRNA abundance (Z-score > 2) GR00366-A-79 10.6 CTNNB1
44 Increased shRNA abundance (Z-score > 2) GR00366-A-81 10.6 SMAD4 TGFBR2 PLAGL2
45 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.6 RET
46 Decreased viability in esophageal squamous lineage GR00235-A 9.93 TGFBR2 SLC26A3 SMAD4 THADA KRAS MLH1
47 Upregulation of Wnt/beta-catenin pathway after WNT3A stimulation GR00016-A 9.1 TGFBR2 SMAD4 MSH2 AXIN2 PLAGL2 GNAS

MGI Mouse Phenotypes related to Adenoma:

43 (show all 22)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.47 GNAS LHCGR KRAS CCND1 AIP AXIN2
2 growth/size/body region MP:0005378 10.45 GNAS LHCGR KRAS CCND1 AIP AXIN2
3 homeostasis/metabolism MP:0005376 10.44 GNAS LHCGR KRAS CCND1 AIP CTNNB1
4 endocrine/exocrine gland MP:0005379 10.43 GNAS LHCGR KRAS AIP AXIN2 CTNNB1
5 cardiovascular system MP:0005385 10.38 KRAS GNAS LHCGR CCND1 AIP AXIN2
6 mortality/aging MP:0010768 10.36 KRAS GNAS CCND1 AIP AXIN2 CTNNB1
7 behavior/neurological MP:0005386 10.35 CTNNB1 KRAS GNAS CCND1 POMC LHCGR
8 digestive/alimentary MP:0005381 10.35 LHCGR KRAS CTNNB1 CCND1 MLH1 PLAGL2
9 immune system MP:0005387 10.3 KRAS GNAS CTNNB1 CCND1 MSH2 POMC
10 integument MP:0010771 10.25 KRAS GNAS CCND1 AIP CTNNB1 POMC
11 nervous system MP:0003631 10.25 KRAS GNAS LHCGR CCND1 AXIN2 CTNNB1
12 embryo MP:0005380 10.22 KRAS CTNNB1 AIP AXIN2 PLAG1 PLAGL1
13 neoplasm MP:0002006 10.21 GNAS KRAS AIP CTNNB1 CCND1 MLH1
14 craniofacial MP:0005382 10.13 CTNNB1 KRAS GNAS CCND1 AXIN2 SMAD4
15 liver/biliary system MP:0005370 10.13 KRAS GNAS LHCGR AIP CTNNB1 POMC
16 limbs/digits/tail MP:0005371 10.1 KRAS GNAS AXIN2 CTNNB1 LHCGR PLAGL1
17 normal MP:0002873 10.02 KRAS GNAS CCND1 AXIN2 CTNNB1 LHCGR
18 no phenotypic analysis MP:0003012 9.97 KRAS GNAS CTNNB1 AXIN2 POMC PLAGL1
19 reproductive system MP:0005389 9.85 KRAS CTNNB1 CCND1 AXIN2 PLAG1 LHCGR
20 renal/urinary system MP:0005367 9.8 CTNNB1 KRAS GNAS LHCGR SMAD4 RET
21 respiratory system MP:0005388 9.61 KRAS GNAS LHCGR CCND1 CTNNB1 PLAGL1
22 skeleton MP:0005390 9.32 KRAS GNAS CTNNB1 CCND1 AXIN2 LHCGR

Drugs & Therapeutics for Adenoma

Drugs for Adenoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 556)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Erythromycin Approved, Investigational, Vet_approved Phase 4 114-07-8 12560
2
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-78-2 2244
3
Clopidogrel Approved Phase 4 120202-66-6, 113665-84-2 60606
4
Pantoprazole Approved Phase 4 102625-70-7 4679
5
Ticlopidine Approved Phase 4 55142-85-3 5472
6
Ecabet Approved, Investigational Phase 4 33159-27-2, 86408-72-2 65781
7 Magnesium citrate Approved Phase 4,Phase 3,Phase 2
8
Magnesium oxide Approved Phase 4 1309-48-4 14792
9
Epinephrine Approved, Vet_approved Phase 4,Phase 3,Phase 2 51-43-4 5816
10 Racepinephrine Approved Phase 4,Phase 3,Phase 2 329-65-7
11
Hydrocortisone Approved, Vet_approved Phase 4,Phase 3,Phase 2 50-23-7 657311 5754
12
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
13
Menthol Approved Phase 4,Phase 3,Phase 1,Phase 2 2216-51-5 16666
14
Octreotide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 83150-76-9 6400441 383414
15
Cabergoline Approved Phase 4,Phase 3,Phase 2 81409-90-7 54746
16
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1 51-61-6, 62-31-7 681
17
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1 159351-69-6 6442177
18
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 1 22916-47-8 4189
19
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 53123-88-9 46835353 6436030 5284616
20
Metformin Approved Phase 4,Phase 2,Phase 1 657-24-9 4091 14219
21
Sunitinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 341031-54-7, 557795-19-4 5329102
22
Somatostatin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 38916-34-6, 51110-01-1 53481605
23
Methylene blue Approved, Investigational Phase 4,Phase 3 61-73-4
24
Celecoxib Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 169590-42-5 2662
25 lanreotide Approved Phase 4,Phase 3,Phase 2 108736-35-2
26
Rabeprazole Approved, Investigational Phase 4 117976-89-3 5029
27
Cefazolin Approved Phase 4 25953-19-9 33255 656510
28
Cefdinir Approved Phase 4 91832-40-5 6915944
29
Cefuroxime Approved Phase 4 55268-75-2 5479529 5361202
30
Clindamycin Approved, Vet_approved Phase 4 18323-44-9 29029
31
Sulfamethoxazole Approved Phase 4 723-46-6 5329
32
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
33
Liraglutide Approved Phase 4 204656-20-2 44147092
34
Zinc Approved, Investigational Phase 4,Phase 3 7440-66-6 32051 23994
35
Clarithromycin Approved Phase 4 81103-11-9 84029
36
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2 77-92-9 311
37
Vitamin C Approved, Nutraceutical Phase 4,Phase 3,Phase 2 50-81-7 54670067 5785
38
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 59-30-3 6037
39
leucovorin Approved, Nutraceutical Phase 4,Phase 2,Phase 3,Phase 1 58-05-9 143 6006
40
Butyric Acid Experimental, Investigational Phase 4 107-92-6 264
41 Pancreatic Polypeptide Investigational Phase 4,Phase 2,Phase 3,Phase 1 59763-91-6
42
Lactitol Investigational Phase 4 585-86-4 3871
43 Adjuvants, Anesthesia Phase 4,Phase 3,Phase 1
44 Anesthetics Phase 4,Phase 3,Phase 2,Phase 1
45 Anticonvulsants Phase 4,Phase 2
46 Autonomic Agents Phase 4,Phase 2,Phase 3,Phase 1
47 Bromides Phase 4
48 Butylscopolammonium Bromide Phase 4
49 Cholinergic Agents Phase 4
50 Cholinergic Antagonists Phase 4

Interventional clinical trials:

(show top 50) (show all 1164)

# Name Status NCT ID Phase Drugs
1 Does the Hyoscine N-Butylbromide Administered During Colonoscopy Increase the Adenoma Detection Rate? Unknown status NCT01609855 Phase 4 Hyoscine Butyl Bromide 20mg/2 ml i.v.;Saline 2 ml i.v.
2 Efficacy Combined Fecal Immunochemical Test-Sigmoidoscopy for the Detection of Advanced Colorectal Neoplasia Unknown status NCT01767870 Phase 4
3 Prophylactic Pancreatic Duct Stent Placement After ESP of Major Papillary Tumors; Prospective, Randomized Study Unknown status NCT01737463 Phase 4
4 Glucagon and Colonoscopy Unknown status NCT02078726 Phase 4 Glucagon;Placebo
5 Erythromycin Treatment for Readthrough of APC Gene Stop Codon Mutation in Familial Adenomatous Polyposis-minors' Adjusted Version Unknown status NCT02354560 Phase 4 Erythromycin
6 Erythromycin Treatment for Readthrough of APC Gene Stop Codon Mutations in Familial Adenomatous Polyposis Unknown status NCT02175914 Phase 4 Erythromycin
7 Participation and Detection Rate Diagnostic of a Colorectal Cancer Screening Program: CT Colonography vs. Flexible Sigmoidoscopy Unknown status NCT01739608 Phase 4
8 Does Early Re-administration of Aspirin/Clopidogrel Increase the Risk of Bleeding From Artificial Ulcer After EMR or ESD? Unknown status NCT01621451 Phase 4 aspirin and/or clopidogrel;aspirin and/or clopidogrel
9 Efficacy of Ecabet Sodium and Proton Pump Inhibitor Combination Therapy in the Treatment of Iatrogenic Ulcer After Endoscopic Submucosal Dissection Unknown status NCT01308177 Phase 4 Ecabet
10 Efficacy and Safety of Split-dose Citrafleet Administered From 2 to 6 Hours Before Morning Colonoscopies Unknown status NCT01481714 Phase 4 Sodium picosulphate, magnesium oxid and citric acid;Sodium picosulphate/magnesium oxide and citric acid
11 Influence of Synacthen Infusion on the Results of Adrenal Venous Sampling in Patient With Primary Aldosteronism Unknown status NCT02127840 Phase 4 Synacthen infusion during adrenal venous sampling
12 Effect of Perioperative Glucocorticoid Replacement on Prognosis of Surgical Patients With Sellar Lesions Unknown status NCT02190994 Phase 4 Hydrocortisone;Prednisone
13 Characterization of Receptors in Non-functioning Pituitary Macroadenomas Unknown status NCT00852501 Phase 4
14 Disease-Specific Questionnaire in Assessing Quality of Life in Patients With Gastrointestinal-Related Neuroendocrine Tumors Unknown status NCT00454376 Phase 4
15 Endoscopy Nurse Participation in Adenoma Detection Rate During Colonoscopy Completed NCT01124266 Phase 4
16 Surgical Debulking of Pituitary Adenomas Completed NCT01371643 Phase 4 Octreotide LAR
17 Comparative Efficacy of Water & Indigo Carmine vs. Water or Air Method on Adenoma Detection Rate (ADR) - a Randomized Controlled Trial (RCT) Completed NCT01607255 Phase 4 Indigo carmine
18 Effect of Gum Chewing on Bowel Cleansing Before Colonoscopy Completed NCT02507037 Phase 4 polyethylene glycol
19 Preoperative Octreotide Treatment of Acromegaly Completed NCT00521300 Phase 4 Octreotide
20 A Multi-centre Study Comparing the Polyp Detection Rate of Two Different Types of Bowel Preparation: a 2-litre Solution (MOVIPREP®) Versus a Hyperosmotic and Stimulant Combined Low Volume Bowel Preparation (Sodium Picosulfate and Magnesium Citrate) Completed NCT01689792 Phase 4 MOVIPREP;CitraFleet
21 Octreotide Efficacy and Safety in First-line Acromegalic Patients Completed NCT00171886 Phase 4 Octreotide
22 Holmium Laser Enucleation of Prostate(HOLEP) vs Greenlight(XPS) Laser Photoselective Vapo-Enucleation of Prostate(PVEP) Completed NCT01494337 Phase 4
23 Adipokine Profile in Patients With Cushing's Disease on Pasireotide Treatment Completed NCT03080181 Phase 4 Pasireotide 0.6 MG/ML
24 Evaluation of the Effects of Different Prostate Surgeries on Urinary and Sexual Function Completed NCT01810068 Phase 4
25 Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly Completed NCT00376064 Phase 4 Octreotide acetate and cabergoline/Octrotide and Somavert
26 Oral Sulfate Solution (SUPREP) Versus Polyethylene Glycol (PEG) Plus Ascorbic Acid Completed NCT02761213 Phase 4 Oral sulfate solution (OSS);2-L PEG/Asc
27 Cardiac Valve Complications in Prolactinomas Treated With Cabergoline Completed NCT00460616 Phase 4 Cabergoline
28 Comparative Study of Postprocessing Imaging Systems for Diminutive Colonic Polyps Completed NCT01133041 Phase 4
29 Prophylactic Octreotide to Prevent Post Duodenal EMR and Ampullectomy Bleeding Recruiting NCT02032784 Phase 4 octreotide
30 Transanal Endoscopic Microsurgery Versus Endoscopic Submucosal Dissection For Large Rectal Adenomas Recruiting NCT01023984 Phase 4
31 Effects of Ilaprazole on Ulcer Healing Rate and Prevention of Gastrointestinal Bleeding in the Patients Undergone ESD. Recruiting NCT02638584 Phase 4 Ilaprazole;Rabeprazole
32 Prophylactic Oral Antibiotics on Sinonasal Outcomes Following Endoscopic Transsphenoidal Surgery for Pituitary Lesions Recruiting NCT03014687 Phase 4 Placebo;Oral Antibiotics cefdinir or trimethoprim/sulfamethoxazole
33 Assessment of Changes in Metabolic Activity in Liver & Skeletal Muscle in Patients Suffering From Acromegaly Recruiting NCT02115906 Phase 4
34 Phase IV Study of the Safety and Efficacy of Everolimus in Adult Patients With Progressive pNET in China Recruiting NCT02842749 Phase 4 everolimus
35 Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly Recruiting NCT02060383 Phase 4 Pasireotide s.c.;Sitagliptin;Liraglutide;Insulin;Pasireotide LAR;Metformin
36 Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study. Recruiting NCT01794793 Phase 4 Pasireotide
37 Effect of H. Pylori Eradication on the Fate of H. Pylori-associated Gastric Polyp Recruiting NCT03065868 Phase 4 H. pylori eradication (Amoxaxillin, Lanston, Clarithromycin)
38 A Comparison of Eleview Versus Hetastarch as Injectate for EMR Active, not recruiting NCT03350217 Phase 4 Eleview;Hetastarch
39 A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors Active, not recruiting NCT01525550 Phase 4 sunitinib
40 GreenLight Laser Photoselective Vaporization of the Prostate vs Plasma Kinetic Vaporization of the Prostate; RCT Active, not recruiting NCT02283684 Phase 4
41 Clinical Effectiveness of Serum Chromogranin A Levels on Diagnostic of Pancreatic Neuroendocrine Tumors Active, not recruiting NCT02759718 Phase 4
42 Evaluation of Colonoscopy With a Specific Device for the Detection of Adenomas Not yet recruiting NCT03436004 Phase 4
43 Comparison Between 3-L and 4-L Polyethylene Glycol in Bowel Preparation Not yet recruiting NCT03356015 Phase 4 4L Polyethylene Glycol;3L Polyethylene Glycol
44 Impact of Reinforced Education by Wechat and Short Message Service on the Quality of Bowel Preparation Not yet recruiting NCT02832869 Phase 4
45 Premedication Dyclonine Improves Visibility During Bowel Cleansing for Colonoscopy Not yet recruiting NCT03352700 Phase 4 3L PEG;3L PEG+Dyclonine Hydrochloride Mucilage
46 Comparative Effectiveness of Split-Dose Colonoscopy Bowel Preparation Regimens Not yet recruiting NCT03298945 Phase 4 Miralax-Gatorade Prep;Golytely
47 A Study of Rofecoxib in Familial Adenomatous Polyposis (FAP) (0966-205)(TERMINATED) Terminated NCT00140894 Phase 4 MK0966; rofecoxib / Duration of Treatment: 24 weeks;Comparator: placebo / Duration of Treatment: 24 weeks
48 Single Arm Post-marketing Study of SC20 Colonoscope Terminated NCT02279836 Phase 4
49 Observational Familial Adenomatous Polyposis Registry Study In Patients Receiving Celecoxib Compared to Control Patients Terminated NCT00151476 Phase 4 Celecoxib
50 A Pilot Study of Pre- and Post-operative Use of Somatuline Depot. Terminated NCT01861717 Phase 4 lanreotide

Search NIH Clinical Center for Adenoma

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Genetic Tests for Adenoma

Anatomical Context for Adenoma

MalaCards organs/tissues related to Adenoma:

38
Pituitary, Colon, Thyroid, Lung, Prostate, Salivary Gland, Testes

Publications for Adenoma

Articles related to Adenoma:

(show top 50) (show all 7570)
# Title Authors Year
1
The Fatty Liver Index: A Simple and Accurate Predictor of Colorectal Adenoma in an Average-Risk Population. ( 29219920 )
2018
2
Universal Sellar Anatomical Reconstruction Using the Sellar Floor Flap after Endoscopic Pituitary Adenoma Surgery. ( 29436283 )
2018
3
A Migratory Mishap: Giant Mediastinal Parathyroid Adenoma. ( 29360437 )
2018
4
Malignant transformation in non-functioning pituitary adenomas (pituitary carcinoma). ( 29299820 )
2018
5
The Effectiveness of Sternocleidomastoid Flap Versus Superficial Musculoaponeurotic System Flap for the Prevention of Frey Syndrome and Facial Depressed Deformity in Parotid Surgery for Pleomorphic Adenoma. ( 29095193 )
2018
6
Safety of cold snare polypectomy for duodenal adenomas in familial adenomatous polyposis: a prospective exploratory study. ( 29351704 )
2018
7
The Angiotensin Type 2 Receptor In A Human Adrenocortical Zona Glomerulosa And In Aldosterone-Producing Adenoma: Low Expression And No Functional Role. ( 29436482 )
2018
8
A case of urachal villous adenoma with high grade dysplasia focally bordering on adenocarcinoma in situ. ( 29321972 )
2018
9
Triptolide inhibits pituitary adenoma cell viability, migration and invasion via ADAM12/EGFR signaling pathway. ( 29288766 )
2018
10
A Novel Application of Structural Equation Modeling Estimates the Association between Oxidative Stress and Colorectal Adenoma. ( 29074536 )
2018
11
Global and targeted circulating microRNA profiling of colorectal adenoma and colorectal cancer. ( 29112225 )
2018
12
Caveolin-1 promotes pituitary adenoma cells migration and invasion by regulating the interaction between EGR1 and KLF5. ( 29309750 )
2018
13
Fecal immunochemical tests in combination with blood tests for colorectal cancer and advanced adenoma detection-systematic review. ( 29435309 )
2018
14
Left-Sided Colectomy: One of the Important Risk Factors of Metachronous Colorectal Adenoma After Colectomy for Colon Cancer. ( 29417332 )
2018
15
Pleomorphic Adenoma of Submandibular Gland with Extensive Cystic Keratinization. ( 29290205 )
2018
16
Promoter hypermethylation may contribute to Ea89cadherin repression in the human salivary carcinoma ex pleomorphic adenoma. ( 29207084 )
2018
17
MicroRNA-378 regulates cell proliferation and migration by repressing RNF31 in pituitary adenoma. ( 29399147 )
2018
18
Association between investigator-measured body-mass index and colorectal adenoma: a systematic review and meta-analysis of 168,201 subjects. ( 29288474 )
2018
19
Postoperative Diabetes Insipidus and Hyponatremia in Children after Transsphenoidal Surgery for Adrenocorticotropin Hormone and Growth Hormone Secreting Adenomas. ( 29395172 )
2018
20
Consensus-driven in-hospital cortisol assessment after ACTH-secreting pituitary adenoma resection. ( 29143885 )
2018
21
Superficially Spreading Signet-Ring Cell Carcinoma Perpendicularly Colliding with Gastric Adenoma: a Rare Case Report. ( 29441461 )
2018
22
Different effects of metformin and insulin on primary and secondary chemoprevention of colorectal adenoma in diabetes type 2: Traditional and Bayesian meta-analysis. ( 29383018 )
2018
23
Mortality in patients with non-functioning pituitary adenoma. ( 29344906 )
2018
24
Inflammation and Fibrosis in Perirenal Adipose Tissue of Patients With Aldosterone-Producing Adenoma. ( 29059354 )
2018
25
Screening of biomarkers for liver adenoma in low-dose-rate gamma-ray-irradiated mice. ( 29424599 )
2018
26
Common module analysis reveals prospective targets and mechanisms of pediatric adrenocortical adenoma and carcinoma. ( 29435068 )
2018
27
Gray scale and doppler ultrasonography features of the carcinoma ex pleomorphic adenoma. ( 29365290 )
2018
28
Chemopreventive Potential of<i>In Vitro</i>Fermented Raw and Roasted Hazelnuts in LT97 Colon Adenoma Cells. ( 29277760 )
2018
29
Unclassified hepatocellular adenoma in a middle-aged woman with glucose intolerance. ( 29116626 )
2018
30
Epigenetic silencing of<i>SMOC1</i>in traditional serrated adenoma and colorectal cancer. ( 29435136 )
2018
31
Role of fine needle aspiration cytology in diagnosis of brown tumor secondary to parathyroid adenoma. ( 29403220 )
2018
32
Mineralocorticoid receptor antagonism protects the aorta from vascular smooth muscle cell proliferation and collagen deposition in a rat model of adrenal aldosterone-producing adenoma. ( 29164516 )
2018
33
Associations of mitochondrial polymorphisms with sporadic colorectal adenoma. ( 29323753 )
2018
34
The tumour microenvironment creates a niche for the self-renewal of tumour-promoting macrophages in colon adenoma. ( 29422500 )
2018
35
CantA_ syndrome with coexisting familial pituitary adenoma. ( 29327300 )
2018
36
Association of retinal nerve fibre layer thickness with quantitative magnetic resonance imaging data of the optic chiasm in pituitary adenoma patients. ( 29398198 )
2018
37
Adenoma detection rate: is it the master key for the colonoscopy quality indicator? ( 29441370 )
2018
38
Adrenal Collision Tumor Composed of Adrenocortical Adenoma and Pheochromocytoma. ( 29363662 )
2018
39
Debulking surgery of pituitary adenoma as a strategy to facilitate definitive stereotactic radiosurgery. ( 29450811 )
2018
40
Targeting CXCR4 (CXC Chemokine Receptor Type 4) for Molecular Imaging of Aldosterone-Producing Adenoma. ( 29279316 )
2018
41
KCNJ5 mutation as a predictor for resolution of hypertension after surgical treatment of aldosterone-producing adenoma. ( 29016532 )
2018
42
Tubular Adenoma of the Breast: A Clinicopathologic Study of a Series of 9 Cases. ( 29449780 )
2018
43
Calneuron 1 Increased Ca2+ in the Endoplasmic Reticulum and Aldosterone Production in Aldosterone-Producing Adenoma. ( 29109191 )
2018
44
Recurrent rearrangements of the PLAG1 and HMGA2 genes in lacrimal gland pleomorphic adenoma and carcinoma ex pleomorphic adenoma. ( 29437290 )
2018
45
Testosterone- and Cortisol-secreting Oncocytic Adrenocortical Adenoma in the Pediatric Age-group. ( 29426273 )
2018
46
Ureteral Nephrogenic Adenoma in Chronic Recreational Ketamine Abuse. ( 29204356 )
2018
47
A thyrotropin-secreting pituitary adenoma treated with radiosurgery: Long-term outcomes. ( 29426625 )
2018
48
Risk category system to identify pituitary adenoma patients with<i>AIP</i>mutations. ( 29440248 )
2018
49
Lacrimal myoepithelial carcinoma ex recurrent pleomorphic adenoma: A clinicopathological report and review of the literature. ( 29387416 )
2018
50
A six-gene panel to label follicular adenoma, low- and high-risk follicular thyroid carcinoma. ( 29298844 )
2018

Variations for Adenoma

Expression for Adenoma

Search GEO for disease gene expression data for Adenoma.

Pathways for Adenoma

Pathways related to Adenoma according to GeneCards Suite gene sharing:

(show all 27)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.89 AXIN2 CCND1 CTNNB1 GNAS KRAS PRL
2
Show member pathways
12.79 AXIN2 CCND1 CTNNB1 KRAS MLH1 MSH2
3
Show member pathways
12.58 AXIN2 CCND1 CTNNB1 KRAS MLH1 SMAD4
4 12.38 AXIN2 CCND1 CTNNB1 GNAS KRAS MLH1
5 12.31 CCND1 CTNNB1 KRAS SMAD4 TGFBR2
6
Show member pathways
12.22 AXIN2 CTNNB1 GNAS KRAS POMC
7
Show member pathways
12.05 CCND1 KRAS SMAD4 TGFBR2
8 12.02 AXIN2 CCND1 CTNNB1 SMAD4 TGFBR2
9 12 AXIN2 CTNNB1 KRAS SMAD4
10
Show member pathways
11.99 CCND1 KRAS SMAD4 TGFBR2
11 11.96 CCND1 KRAS MLH1 MSH2
12 11.89 CCND1 CTNNB1 KRAS SMAD4
13 11.82 CCND1 CTNNB1 KRAS MSH2 SMAD4 TGFBR2
14 11.79 KRAS SMAD4 TGFBR2
15 11.79 CCND1 KRAS SMAD4 TGFBR2
16 11.77 CTNNB1 GNAS POMC
17 11.76 CCND1 CTNNB1 SMAD4
18 11.68 AXIN2 CCND1 CTNNB1
19 11.64 CTNNB1 SMAD4 TGFBR2
20 11.54 CTNNB1 SMAD4 TGFBR2
21 11.49 AXIN2 CCND1 CTNNB1 GNAS KRAS MLH1
22 11.48 AXIN2 CCND1 CTNNB1
23 11.46 CTNNB1 SMAD4 TGFBR2
24 11.39 AIP KRAS PLAGL1 RET
25 11.1 CTNNB1 KRAS SMAD4 TGFBR2
26 11.03 AXIN2 CCND1 CTNNB1
27 10.73 CTNNB1 SST

GO Terms for Adenoma

Cellular components related to Adenoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 beta-catenin destruction complex GO:0030877 8.96 AXIN2 CTNNB1
2 mismatch repair complex GO:0032300 8.62 MLH1 MSH2

Biological processes related to Adenoma according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell proliferation GO:0008285 9.92 AXIN2 CTNNB1 SMAD4 SST TGFBR2
2 in utero embryonic development GO:0001701 9.81 CTNNB1 MSH2 SMAD4 TGFBR2
3 female pregnancy GO:0007565 9.73 GNAS KRAS PRL
4 isotype switching GO:0045190 9.57 MLH1 MSH2
5 positive regulation of cAMP-mediated signaling GO:0043950 9.55 GNAS LHCGR
6 positive regulation of isotype switching to IgG isotypes GO:0048304 9.54 MLH1 MSH2
7 response to steroid hormone GO:0048545 9.5 CCND1 SST TGFBR2
8 hair follicle placode formation GO:0060789 9.49 CTNNB1 GNAS
9 trachea formation GO:0060440 9.48 CTNNB1 TGFBR2
10 maintenance of DNA repeat elements GO:0043570 9.46 AXIN2 MSH2
11 positive regulation of isotype switching to IgA isotypes GO:0048298 9.43 MLH1 MSH2
12 response to drug GO:0042493 9.43 CCND1 CTNNB1 GNAS RET SST TGFBR2
13 somatic recombination of immunoglobulin gene segments GO:0016447 9.4 MLH1 MSH2
14 trachea morphogenesis GO:0060439 9.37 CTNNB1 TGFBR2
15 regulation of centromeric sister chromatid cohesion GO:0070602 9.26 AXIN2 CTNNB1
16 somatic recombination of immunoglobulin genes involved in immune response GO:0002204 9.16 MLH1 MSH2
17 positive regulation of epithelial to mesenchymal transition GO:0010718 8.92 AXIN2 CTNNB1 SMAD4 TGFBR2

Molecular functions related to Adenoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mismatched DNA binding GO:0030983 9.16 MLH1 MSH2
2 guanine/thymine mispair binding GO:0032137 8.96 MLH1 MSH2
3 I-SMAD binding GO:0070411 8.8 AXIN2 CTNNB1 SMAD4

Sources for Adenoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16